Cosmos Health Inc.

COSM • Medical - Pharmaceuticals

$0.27

▲ +0.01 (+2.59%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DÉBILDébilConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil histórico débil. La evidencia actual no sostiene una relación riesgo/retorno favorable.

Capitalización

$16.37M

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 21 ago 2026, 12:18 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$0.27

Change2.59%

Shares Out59.92M

Market Cap$16.37M

Enterprise Value$21.76M

52W Range0.16 - 1.32

Beta4.17

P/E-0.67

P/S0.22

P/B0.79

P/FCF-1.43

EV/Sales0.30

Price$0.27

Change2.59%

Shares Out59.92M

Market Cap$16.37M

Enterprise Value$21.76M

52W Range0.16 - 1.32

Beta4.17

P/E-0.67

P/S0.22

P/B0.79

P/FCF-1.43

EV/Sales0.30

EV/EBITDA-1.24

EV/FCF-1.90

Earnings Yield-148.99%

FCF Yield-69.93%

Dividend Yield0.00%

Gross Margin12.10%

Oper. Margin-25.34%

Profit Margin-29.33%

Debt/Eq1.08

Current Ratio1.00

Quick Ratio0.85

Volume4.24M

Avg Volume8.83M

EPS Surprise0.00

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

43/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

95/100

Por qué este puntaje▼

Tendencia de crecimiento negativaRentabilidad débil

Analyst view

No analyst data available now.

Resumen de la compañía

IPO: 7/23/2010

Industria: Medical - Pharmaceuticals

P/B i: 0.79

Deuda / Patrimonio i: 1.08

Margen operativo: -25.34%

Margen neto: -29.33%

ROE i: -

ROIC: -

Salud financiera

Puntaje9 / 20

Deuda / Patrimonio: 1.08

Ratio corriente: 1.00

Ratio rápido: 0.85

Estado: Moderate

Transacciones internas

Actividad reciente de ejecutivos e insiders

⚠ 2 venta interna de alto volumens detectadas

Siokas Grigorios

Transacción: 07/30/2026

COMPRA

Cambio

+349,825

Precio

$0.20

Presentación

07/31/2026

Tipo

COMPRA

Siokas Grigorios

Transacción: 07/29/2026

COMPRA

Cambio

+766,284

Precio

$0.18

Presentación

07/30/2026

Tipo

COMPRA

Terzis Georgios

Transacción: 07/29/2026

COMPRA

Cambio

+328,407

Precio

$0.18

Presentación

07/30/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Siokas Grigorios	COMPRA	+349,825	$0.20	07/30/2026	07/31/2026
Siokas Grigorios	COMPRA	+766,284	$0.18	07/29/2026	07/30/2026
Terzis Georgios	COMPRA	+328,407	$0.18	07/29/2026	07/30/2026
Terzis Georgios	COMPRA	+168,135	$0.25	06/16/2026	06/17/2026
Siokas Grigorios	COMPRA	+218,447	$0.21	06/11/2026	06/12/2026
Siokas Grigorios	COMPRA	+701,447	$0.23	06/10/2026	06/12/2026
Siokas Grigorios	VENTA	-2,350,000	Not reported	05/19/2026	06/11/2026
Siokas Grigorios	COMPRA	+2,350,000	$0.28	05/19/2026	06/11/2026
Terzis Georgios	VENTA	-850,000	Not reported	05/19/2026	06/11/2026
Terzis Georgios	COMPRA	+850,000	$0.28	05/19/2026	06/11/2026
Bhutawala Suhel	VENTA	-20,000	Not reported	05/19/2026	06/11/2026
Bhutawala Suhel	COMPRA	+20,000	$0.28	05/19/2026	06/11/2026
Aslidis Anastasios	VENTA	-40,000	Not reported	05/19/2026	06/11/2026
Aslidis Anastasios	COMPRA	+40,000	$0.28	05/19/2026	06/11/2026
Demetriades Demetrios G.	VENTA	-20,000	Not reported	05/19/2026	06/11/2026
Demetriades Demetrios G.	COMPRA	+20,000	$0.28	05/19/2026	06/11/2026
Hoidas John James	VENTA	-20,000	Not reported	05/19/2026	06/11/2026
Hoidas John James	COMPRA	+20,000	$0.28	05/19/2026	06/11/2026
Karkantzos Theodoros Christos	VENTA	-35,000	Not reported	05/19/2026	06/11/2026
Karkantzos Theodoros Christos	COMPRA	+20,000	$0.28	05/19/2026	06/11/2026

Sobre la compañía

Cosmos Health Inc.

Cosmos Health Inc. functions as a vertically integrated pharmaceutical firm, providing its own line of branded and generic medicines, nutraceuticals, non-prescription drugs, healthcare and infant products, medical devices, and various other goods. These are distributed via its established channels and an e-commerce marketplace. The company actively seeks, obtains, develops, and commercializes solutions designed to improve patients' well-being and health outcomes. Supporting these operations, it maintains distribution centers in both Greece and the United Kingdom, alongside a dedicated warehousing facility. Its clientele includes wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health Inc. was established in 2009 and has its headquarters in Chicago, Illinois.

Fuente - Link

Competidores

CASI CLSD FEMY IINN LSTA MTVA NCNA NXGL PASG SCYX

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Cosmos Health: A Company Transformed — 2026 Year-to-Date

A Comprehensive Corporate Summary — January 1, 2026 through August 31, 2026 Revenue record set three consecutive quarters: FY2025 $65.3M (+20%) → Q1 2026 $17.93M (+31%) → Q2 2026 $18.99M (+28.8%) → H1 2026 $36.91M (+29.7%). Annualized adjusted run-rate exceeds $75M.

GlobeNewsWire

Cosmos Health Strengthens Balance Sheet and Streamlines Capital Structure; Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution From Conversions

$8 million senior secured ATW convertible note satisfied, together with all accrued interest, twelve months ahead of its August 2027 maturity and eliminating any further dilution Simplified capital structure, with no effective shelf registration statement or ATM program, and no structured warrants or variable interest rate instruments without a floor Operating cash requirements reduced by more than 30%, reflecting revenue growth, operating efficiencies, improved operating leverage and cost control Strong liquidity position, with a diversified asset base supporting the Company's next growth phase and Bitcoin holdings now in a gain position following recent market strength $5.0 million share repurchase program underway, following record second-quarter and first-half revenue, with momentum continuing into Q3 2026 CHICAGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") ( NASDAQ: COSM ), a diversified, vertically integrated global healthcare group, today announced that its $8.0 million senior secured convertible ATW note has been retired, and provided an update on its capital structure and operating cash requirements. These financial milestones come at a time of accelerating growth, with Cosmos Health delivering its highest second-quarter and first-half revenue in Company history, contribution from every core division and momentum continuing into Q3 2026.

GlobeNewsWire

Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories

Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories.

GlobeNewsWire

Cosmos Health Enters Saudi Arabia Through Exclusive Distribution Agreement With Innova Healthcare; Secures Initial Purchase Order of 126,000 Sky Premium Life Units, With More Than 5 Million Units Expected Over Initial 5-Year Term

Cosmos Health Enters Saudi Arabia. Signs Exclusive Distribution Agreement With Innova Healthcare; Secures Purchase Order of 126,000 Sky Premium Life Units.

GlobeNewsWire

Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway

Highest Q2 and H1 revenue in Company history, reflecting strength across all core segments and reaching a new milestone with an adjusted annualized revenue run-rate exceeding $75 million Continued progress toward profitability targets, with adjusted gross profit reaching approximately $7.4 million on an annualized basis, adjusted gross margin expanding 165 basis points to 9.54%, and adjusted EBITDA improving 13.8% Demonstrated operating leverage and disciplined inventory management, with Q2 operating expenses growing at roughly half the rate of revenue and first-half inventory down 21.8% despite nearly 30% revenue growth Strengthened balance sheet, with total liabilities decreasing 13.3% by $6.27 million, stockholders' equity rising 12.2% to $20.67 million, and the liabilities-to-assets ratio improving by 550 basis points Liquid assets of $4.15 million, comprising cash, marketable securities and digital assets Share repurchase program actively underway as record momentum continues into Q3 2026 CHICAGO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today reported financial results for the second quarter and six months ended June 30, 2026. Second Quarter and First Half 2026 Financial Highlights Income Statement Cosmos Health delivered its highest second-quarter and first-half revenue in Company history, with growth contributed by every core division.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-21	-0.06	-0.06	0
2026-05-20	-0.01	-0.33	-0.32
2025-11-14	-0.01	-0.17	-0.16
2025-08-18	0.01	-0.06	-0.07
2025-05-15	-0.03	0.01	0.04
2025-04-15	-0.09	-0.08	0.01
2024-11-14	-0.11	-0.45	-0.34
2024-08-20	-0.14	-0.04	0.1
2024-08-06	-0.2	0.1	0.3
2024-07-02	-0.14	-0.04	0.1